ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
1 hedge funds and large institutions have $5K invested in ELITE PHARMACEUTICAL in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
62% less capital invested
Capital invested by funds: $13.1K → $5K (-$8.14K)
67% less funds holding
Funds holding: 3 → 1 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAFL
Jay A. Fishman Ltd
Troy,
Michigan
|
-$5.14K |
| 2 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HCM
1
Highlander Capital Management
Short Hills,
New Jersey
| $5K | – | – | – |
|
|
JAFL
2
Jay A. Fishman Ltd
Troy,
Michigan
| – | -$5.14K | -60,000 | Closed |
|
|
3
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$4K | -48,778 | Closed |
|
ELI Hedge Fund Activity: Q4 2019 in Review
1 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q4 2019, worth a combined $5K — down 62% from $13.1K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ELI and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Jay A. Fishman Ltd, exiting entirely with an estimated $5.14K sold.
- 1 institutional investor held ELITE PHARMACEUTICAL (ELI) as of Q4 2019, down from 3 in Q3 2019.
- Funds reported $5K of ELITE PHARMACEUTICAL stock for Q4 2019, down 62% quarter-over-quarter.
- 0 funds opened new ELITE PHARMACEUTICAL positions in Q4 2019 and 2 closed out, a net change of -2 holders.
- The largest ELITE PHARMACEUTICAL seller in Q4 2019 was Jay A. Fishman Ltd, an estimated $5.14K sold.
Based on aggregated 13F filings for Q4 2019.